Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations

Eva Renee Barnett, CFO of Immunovant, Inc., sold 4,105 shares of common stock on January 8, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On January 8, 2025, Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 4,105 shares of Immunovant's common stock.
• The sale was executed at a weighted average price of $24.1 per share, with individual transactions ranging from $23.91 to $24.60 per share.
• The shares were sold to cover tax withholding obligations associated with the vesting of 8,937 restricted stock units (RSUs) on January 4, 2025.
• This sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction and does not represent a discretionary transaction by Ms. Barnett.
• Following the reported transaction, Ms. Barnett still beneficially owns 327,064 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on shareholders, but it is unlikely to be significant as it was for tax obligations.

Key Dates